Insmed (INSM) Receives News Sentiment Rating of 0.13
Media headlines about Insmed (NASDAQ:INSM) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Insmed earned a news impact score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.4307111071507 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Brokerages Expect Insmed, Inc. (INSM) to Announce -$0.66 EPS (americanbankingnews.com)
- Insmed, Inc. (INSM) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Insmed, Inc. Fundamental Analysis : November 30, 2017 (finance.yahoo.com)
- Today’s Research Reports on Stocks to Watch: Horizon Pharma and Insmed Incorporated (finance.yahoo.com)
- Insmed to Present at the Nasdaq 37th Annual Investor Conference (finance.yahoo.com)
A number of analysts have recently weighed in on the stock. BidaskClub cut shares of Insmed from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Cowen restated a “buy” rating and issued a $54.00 price objective on shares of Insmed in a research note on Friday, November 3rd. ValuEngine upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Insmed in a research note on Wednesday, September 6th. Finally, Leerink Swann boosted their price objective on shares of Insmed from $27.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $34.50.
Insmed (NASDAQ:INSM) opened at $28.49 on Tuesday. Insmed has a one year low of $11.49 and a one year high of $32.94. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13.
In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total transaction of $487,500.00. Following the completion of the transaction, the director now directly owns 71,131 shares in the company, valued at approximately $2,311,757.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Melvin Md Sharoky sold 50,000 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $27.37, for a total transaction of $1,368,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 110,000 shares of company stock valued at $3,191,150. Corporate insiders own 5.10% of the company’s stock.
WARNING: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/12/04/insmed-insm-receives-news-sentiment-rating-of-0-13.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.